Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Jocelyn Y HsuNathan D SeligsonJohn L HaysWayne O MilesJames L ChenPublished in: JCO precision oncology (2022)
CDK4/6 inhibitors represent a major breakthrough for targeted cancer treatment. CDK4/6 inhibitor use in sarcoma has led to limited, but significant, early clinical success. Targeted future clinical research will be key to unlocking the potential of CDK4/6 inhibition in sarcoma.